For more than a decade, Qu Biologics has worked to capture the value of our innovations in what is now a worldwide patent portfolio. The portfolio is tailored to our lead products, and based on our pioneering insights in the field of site specific immunotherapy (SSI). The Company works to coordinate our intellectual property strategy with our corporate priorities, both of which evolve in concert with our ongoing discoveries. With over 27 issued patents worldwide, including patents covering the treatment of a very wide variety of cancers, and many more applications pending, Qu Biologics continues to build on our already strong proprietary position in the field of immunomodulatory therapies for cancers and other immune-related and chronic inflammatory diseases.
Current information on the patents and applications of Qu Biologics is available from patent offices around the world:
U.S. Patents: http://portal.uspto.gov/pair/PublicPair
European Patents: http://www.epo.org/searching.html